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Abstract	  There	  is	  no	  broad-­‐based	  antiviral	  medication	  available	  today;	  there	  are	  specific	  antivirals,	  for	  example,	  the	  antiretroviral	  for	  HIV.	  	  However,	  these	  specific	  antivirals	  are	  not	  available	  in	  each	  country	  and	  can	  be	  problematic	  for	  specific	  patients.	  	  Chitosan	  is	  proposed	  as	  a	  possible	  broad-­‐based	  antiviral,	  which	  has	  already	  demonstrated	  antibacterial	  properties,	  antiviral	  properties	  in	  plants,	  is	  used	  for	  wound	  healing	  and	  as	  a	  hydrogel	  among	  other	  medical	  applications.	  The	  methods	  used	  are	  transfection	  of	  NIH-­‐3T3	  cells	  with	  GFP-­‐adenovirus	  with	  0.1%,	  0.5%,	  and	  1%	  chitosan	  added	  to	  virus	  prior	  to	  transfection.	  	  Fluorescence	  microscopy	  and	  flow	  cytometry	  data	  has	  validated	  that	  the	  use	  of	  0.1%	  chitosan	  added	  to	  virus	  before	  transfection	  reduced	  the	  percentage	  of	  fluorescence	  of	  gfp	  from	  72%	  to	  1.9%,	  suggesting	  a	  70%	  percentage	  difference	  of	  transfection.	  	  Based	  on	  these	  findings,	  it	  is	  proposed	  that	  chitosan	  could	  be	  a	  broad-­‐based	  antiviral	  medication.	  	  Future	  directions	  include	  the	  adding	  chitosan	  after	  transfection,	  use	  of	  other	  viruses,	  and	  employing	  studies	  in	  animal	  models	  to	  test	  in-­‐vivo.	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Background	  Many	  viruses	  of	  today’s	  world	  go	  uncured	  from	  a	  lack	  of	  a	  broad-­‐based	  antiviral	  medication	  that	  would	  be	  comparable	  to	  antibiotics	  for	  bacterial	  infections.	  	  Treatments	  are	  available	  to	  patients	  to	  help	  with	  the	  symptoms	  of	  a	  viral	  infection	  or	  to	  help	  subdue	  the	  virus	  from	  spreading	  or	  remaining	  active	  in	  their	  body.	  	  Currently	  antiretroviral	  treatments	  that	  target	  cell	  entry,	  transcription	  of	  the	  virus,	  and	  viral	  progression	  are	  helping	  to	  reduce	  the	  mortality	  rates	  of	  viruses	  such	  as	  HIV.1	  This	  treatment	  has	  been	  made	  available	  to	  15.8	  million	  of	  the	  36.9	  million	  people	  living	  with	  HIV	  worldwide.2	  Although	  this	  amount	  of	  people	  receiving	  treatment	  is	  almost	  50%,	  many	  third	  world	  countries	  do	  not	  benefit	  from	  the	  antiretroviral	  treatment.	  	  Also,	  if	  a	  patient	  does	  receive	  the	  treatment,	  there	  can	  be	  complications	  such	  as	  resistance	  and	  drug	  toxicity.3	  This	  treatment	  also	  requires	  regular	  monitoring	  of	  the	  CD4	  levels	  in	  the	  blood	  to	  adjust	  medication	  as	  needed	  which	  is	  not	  always	  feasible	  for	  the	  patient.4	  Other	  viruses	  that	  are	  prevalent	  and	  outbreaks	  have	  occurred	  recently	  is	  Ebola	  and	  the	  Zika	  virus.	  	  Ebola	  virus	  has	  no	  cure	  or	  antiretroviral	  with	  the	  most	  concentrated	  outbreaks	  in	  West	  Africa.5	  The	  Ebola	  outbreak	  has	  declined	  in	  West	  Africa	  since	  2014,	  but	  there	  is	  an	  estimation	  of	  11,316	  deaths	  and	  28,639	  cases.6	  The	  Zika	  virus	  also	  has	  no	  treatment	  or	  cure	  with	  an	  outbreak	  that	  started	  in	  2015	  originating	  in	  Africa,	  Southeast	  Asia	  and	  Pacific	  Islands	  and	  now	  has	  spread	  to	  the	  Americas	  and	  many	  countries.7	  The	  Zika	  virus	  has	  been	  linked	  to	  microcephaly	  in	  infants	  born	  to	  mothers	  that	  have	  contracted	  the	  Zika	  virus	  which	  is	  a	  lifelong	  disease	  that	  can	  cause	  many	  health	  conditions.8	  
There	  are	  many	  clinical	  research	  efforts	  being	  made	  to	  discover	  an	  antiviral	  treatment	  or	  cure	  for	  the	  above	  viruses	  and	  viral	  infections	  in	  general.	  This	  study	  employs	  the	  use	  of	  chitosan	  as	  a	  possible	  antiviral	  medication.	  	  Chitosan	  is	  a	  natural	  polysaccharide	  biomaterial	  found	  on	  the	  shells	  of	  crustaceans,	  for	  chemical	  formula	  see	  figure	  one.9	  This	  material	  is	  biocompatible	  and	  used	  in	  many	  medical	  applications.	  The	  most	  common	  medical	  applications	  of	  chitosan	  include	  wound	  healing,	  chitosan	  as	  a	  hydrogel,	  drug	  delivery	  using	  chitosan,	  and	  as	  a	  dilutent.10	  Among	  chitosan’s	  uses,	  it	  also	  has	  been	  shown	  to	  display	  antiviral	  and	  antibiotic	  characteristics.10	  
Figure	  1.	  	  Chemical	  structure	  of	  chitosan.	  
Recently,	  studies	  have	  demonstrated	  chitosan	  to	  not	  only	  be	  effective	  in	  delivering	  antibiotics	  when	  loaded	  with	  antibiotics	  for	  wound	  healing	  applications,	  but	  has	  presented	  to	  have	  antibiotic	  effects	  alone.11	  The	  molecular	  weight	  of	  chitosan	  has	  proven	  to	  be	  a	  key	  role	  in	  the	  antibiotic	  effects.12	  It	  appears	  that	  lower	  molecular	  weights	  of	  chitosan	  are	  more	  successful	  for	  antibiotic	  activity	  than	  higher	  molecular	  weights.12	  In	  addition	  to	  antibiotic	  activity,	  chitosan	  has	  shown	  antiviral	  properties	  in	  plants.13	  In	  a	  study	  performed	  by	  Kulikov,	  the	  molecular	  weight	  of	  
chitosan	  also	  was	  crucial	  for	  antiviral	  effects,	  also	  with	  lower	  concentration	  working	  better	  than	  high.13	  	  	  Chitosan	  is	  proposed	  in	  this	  study	  as	  a	  material	  targeted	  for	  antiviral	  treatment	  with	  adenovirus	  in	  NIH-­‐3T3	  mice	  cells.	  	  Adenovirus	  is	  a	  common	  virus	  that	  accounts	  for	  common	  cold	  like	  symptoms	  usually	  in	  child	  respiratory	  infections.14	  Techniques	  to	  measure	  the	  transfection	  rates	  of	  the	  cells	  with	  and	  without	  chitosan	  will	  be	  by	  fluorescence	  microscopy	  and	  flow	  cytometry.	  	  The	  adenovirus	  used	  in	  this	  study	  is	  engineered	  with	  green	  fluorescence	  protein	  (gfp),	  so	  when	  the	  cell	  is	  transfected	  and	  replicates,	  the	  green	  fluorescence	  protein	  will	  become	  visible	  under	  its	  excitation	  wavelengths	  using	  a	  FITC	  filter.15	  Figure	  2	  displays	  the	  excitation	  and	  emission	  wavelengths	  for	  GFP,	  and	  the	  FITC	  wavelength	  ranges	  in	  figure	  3.	  
Figure	  216.	  Exictaion	  and	  emission	  wavlengths	  of	  GFP.	  Excitation	  peaks	  at	  450nm,	  and	  
emission	  peaks	  approximately	  530	  nm.	  
Figure	  317.	  Excitation	  and	  emission	  wavlengths	  of	  FITC,	  excitation	  peaking	  around	  
480nm,	  emission	  peaking	  around	  530	  nm.	  
Once	  the	  fluorescent	  molecule	  is	  excited	  at	  its	  excitation	  wavelength,	  it	  jumps	  up	  to	  the	  excitation	  energy	  level.	  	  After	  that	  the	  molecule	  energy	  decays	  down	  to	  its	  emission	  energy	  level	  when	  the	  image	  is	  captured.18	  A	  few	  disadvantages	  to	  fluorescent	  imaging	  is	  there	  is	  no	  intrinsic	  qualitative	  analysis	  and	  the	  risk	  of	  photo	  bleaching	  the	  fluorophore	  molecule	  is	  prevalent	  which	  prevents	  prolonged	  exposure	  to	  light	  and	  prolonged	  imaging.	  	  Also,	  photo	  bleaching	  can	  occur	  before	  imaging	  which	  can	  result	  in	  false	  negatives.18	  To	  counterbalance	  the	  disadvantages	  of	  fluorescent	  imaging,	  flow	  cytometry	  provides	  the	  quantitative	  results	  desired.	  	  Flow	  cytometry	  is	  a	  laser	  based	  sorting	  tool	  for	  dyed	  or	  inherently	  fluorescent	  molecules.	  	  Since	  our	  sample	  is	  already	  tagged	  with	  GFP	  prior	  to	  use,	  no	  dying	  was	  necessary.	  	  The	  machine	  forces	  each	  cell	  out	  of	  the	  nozzle	  one	  by	  one.	  As	  the	  cells	  go	  through	  one	  at	  a	  time	  the	  specified	  laser,	  FITC	  in	  this	  case,	  excites	  the	  GFP	  inside	  the	  cell.	  	  If	  the	  cell	  fluoresces	  then	  it	  is	  sorted	  in	  one	  compartment,	  if	  it	  does	  not,	  it	  is	  sorted	  differently,	  displayed	  in	  figure	  4.19	  The	  
flow	  cytometer	  also	  counts	  the	  number	  of	  cells	  present	  in	  each	  sample	  and	  determines	  their	  size	  and	  shape.	  
Figure	  419.	  Schematic	  of	  flow	  cytometry	  using	  fluorescent	  exiting	  laser,	  FITC.	  
Methods	  The	  experiments	  used	  to	  transfect	  NIH-­‐3T3	  cells	  with	  adenovirus	  were	  to	  incubate	  a	  soluable	  chitosan	  (protosan)	  with	  the	  adenovirus	  prior	  to	  exposing	  the	  cells	  to	  virus.	  	  The	  experimental	  process	  consisted	  of	  seeding	  the	  cells	  in	  a	  24-­‐well	  plate,	  transfecting	  the	  cells	  with	  virus+chitosan,	  then	  analyzing	  through	  fluorescence	  microscopy	  and	  flow	  cytometry.	  
	  
Cell	  Passaging	  	   NIH-­‐3T3	  cells	  were	  housed	  in	  a	  cell	  culture	  flask	  at	  37	  degrees	  Celsius	  for	  incubation	  times.	  DMEM	  high	  glucose	  media	  with	  0.5%	  L-­‐Glutamate,	  0.5%	  penicillin/streptomycin	  antibiotic	  and	  10%	  Fetal	  Bovine	  Serum	  was	  used	  for	  cell	  culture	  media.	  Every	  4-­‐5	  days,	  depending	  on	  cell	  population	  the	  cells	  were	  passaged.	  	  The	  old	  media	  was	  aspirated	  out,	  and	  3	  ml	  of	  diluted	  trypsin	  was	  added	  and	  incubated	  for	  5	  minutes.	  	  The	  cells	  were	  collected	  and	  centrifuged	  after	  adding	  fresh	  7ml	  of	  media	  for	  5	  minutes	  at	  1400	  rpm.	  	  The	  media/trypsin	  solution	  was	  aspirated	  out,	  and	  new	  media	  was	  used	  for	  suspension	  of	  the	  cells.	  	  The	  cells	  were	  counted	  using	  a	  hemocytometer,	  and	  roughly	  10%	  of	  the	  population	  was	  added	  to	  2	  new	  cell	  culture	  flasks	  with	  13ml	  of	  fresh	  media.	  	  All	  cell	  passaging	  was	  done	  under	  cell	  culture	  hood,	  and	  sterile	  techniques	  using	  ethanol	  sterilization	  was	  used	  to	  decrease	  contamination.	  	  
Cell	  Counting	  	   After	  the	  cells	  were	  centrifuged	  and	  suspended	  in	  5	  ml	  of	  new	  media	  after	  being	  collected	  from	  the	  cell	  culture	  flask,	  100	  ul	  of	  cells	  were	  collected	  and	  mixed	  with	  100	  ul	  of	  trypan	  blue,	  for	  cell	  staining.	  	  10ul	  of	  this	  solution	  was	  injected	  into	  the	  hemocytometer	  device	  wells,	  pictured	  in	  figure	  5.	  
	  
Figure	  5.	  Hemocytometer	  device	  wells.	  	  Wells	  6,7,9,	  and	  10	  are	  used	  for	  cell	  counting.	  	  	   The	  cells	  were	  counted	  in	  wells	  six,	  seven,	  nine,	  and	  ten.	  	  The	  numbers	  of	  cells	  in	  each	  well	  were	  added	  and	  averaged.	  	  Using	  equation	  one,	  the	  number	  of	  cells	  per	  milliliter	  was	  calculated.	  	   𝐶𝑒𝑙𝑙𝑠𝑚𝑖𝑙𝑙𝑖𝑙𝑖𝑡𝑒𝑟 = 𝑐𝑒𝑙𝑙𝑠  𝑐𝑜𝑢𝑛𝑡𝑒𝑑  𝑖𝑛  𝑡ℎ𝑒  𝑓𝑜𝑢𝑟  𝑤𝑒𝑙𝑙𝑠 ∗ 𝑡𝑟𝑦𝑝𝑎𝑛  𝑏𝑙𝑢𝑒  𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛  𝑓𝑎𝑐𝑡𝑜𝑟4 ∗ 10,000	  
(Equation	  1)	  	  
Cell	  Seeding	  	   The	  cells	  were	  passaged	  as	  above	  and	  counted	  using	  a	  hemocytometer.	  	  For	  experiments,	  200,000	  cells	  were	  added	  to	  each	  well	  in	  the	  24-­‐well	  plate.	  	  When	  seeding	  for	  new	  culture,	  approximately	  500,000	  cells	  were	  added	  to	  a	  new	  flask.	  	  
Adenovirus	  Alloquating	  
	   Upon	  receiving	  new	  virus,	  it	  was	  immediately	  alloquated	  to	  avoid	  repeated	  freeze-­‐thaw	  cycles	  to	  the	  virus,	  which	  diminishes	  viral	  ability.	  	  Green	  fluorescent	  protein	  adenovirus,	  gfp-­‐ad	  ,cat#	  1060,	  200ul	  of	  106	  PFU/ml	  was	  used	  from	  vectorbiolabs.	  The	  virus	  was	  alloquated	  into	  200	  MOI	  micro	  centrifuge	  tubes	  with	  DMEM	  as	  the	  storage	  buffer	  media	  and	  stored	  at	  -­‐80	  degrees	  Celsius.	  	  
Transfection	  without	  chitosan	  
	   Initial	  transfection	  tests	  and	  upon	  receiving	  new	  virus,	  the	  transfection	  of	  the	  3T3	  cells	  were	  done.	  	  The	  cells	  were	  seeded	  at	  200,00	  per	  well	  in	  a	  24-­‐well	  plate	  with	  a	  gap	  in	  between	  the	  first	  and	  third	  column	  with	  no	  cells	  seeded	  to	  keep	  the	  virus	  from	  transferring	  from	  positive	  over	  to	  negative	  control	  wells.	  	  The	  cells	  are	  incubated	  for	  24	  hours	  to	  adhere	  to	  the	  surface	  of	  the	  wells.	  	  Following	  incubation,	  the	  virus	  was	  thawed	  in	  an	  ice	  bath	  and	  the	  cell	  media	  was	  aspirated	  from	  the	  wells.	  The	  negative	  control	  was	  replenished	  with	  new	  media,	  the	  gap	  remained	  in	  between	  the	  negative	  control	  and	  transfected	  cell	  well	  columns.	  	  The	  third	  column	  was	  transfected	  at	  20	  MOI,	  the	  fourth	  at	  50	  MOI,	  fifth	  at	  75	  MOI	  and	  last	  at	  100	  MOI.	  	  The	  cells	  were	  put	  back	  into	  the	  37-­‐degree	  incubation	  chamber	  and	  left	  for	  12-­‐24	  hours.	  	  All	  transfection	  was	  done	  under	  the	  cell	  culture	  hood	  with	  the	  lights	  off	  to	  reduce	  bleaching.	  	  
Transfection	  with	  Chitosan	  
Transfection	  with	  chitosan	  differed	  only	  at	  the	  transfection	  phase.	  	  All	  experimental	  steps	  are	  held	  constant	  with	  seeding	  into	  the	  24-­‐well	  plate	  and	  incubation.	  	  The	  virus	  was	  thawed	  in	  the	  ice	  bath	  per	  usual,	  and	  during	  this	  time	  the	  chitosan	  was	  measured	  out.	  	  Three	  samples	  of	  chitosan	  were	  measured	  out	  for	  0.1%,	  0.5%,	  and	  1%	  chitosan.	  For	  0.1%	  in	  1	  ml	  of	  virus/media	  solution,	  1mg	  was	  weighed,	  5mg	  for	  0.5%	  and	  10mg	  for	  1%.	  	  The	  chitosan	  virus	  solution	  was	  incubated	  for	  15	  minutes	  on	  the	  shaker	  at	  37	  degrees	  Celsius	  or	  until	  chitosan	  was	  in	  solution.	  Once	  the	  chitosan/virus	  solution	  was	  ready,	  the	  cells	  were	  transfected	  and	  incubated	  for	  12-­‐24	  hours	  at	  37	  degrees	  Celsius.	  	  All	  transfection	  was	  done	  with	  cell	  culture	  hood	  lights	  off.	  	  
Fluorescence	  Microscopy	  	   Prep	  	  	   	   The	  cells	  were	  washed	  three	  times	  with	  PBS	  following	  the	  transfection	  incubation.	  200	  ul	  of	  PBS	  was	  kept	  in	  the	  well	  for	  imaging.	  	  All	  washing	  done	  with	  cell	  culture	  hood	  lights	  off.	  	   Imaging	  
	   	   After	  turning	  on	  the	  microscope	  and	  letting	  it	  warm	  up	  for	  fifteen	  minutes,	  the	  wells	  were	  placed	  on	  the	  microscope-­‐imaging	  platform.	  	  The	  eyepiece	  was	  used	  in	  conjunction	  with	  the	  computer	  software	  imaging	  modality.	  	  Once	  a	  satisfactory	  region	  was	  selected	  in	  normal	  light,	  the	  image	  was	  captured	  in	  10x	  and	  20x.	  	  Then	  the	  light	  source	  was	  switched	  to	  FIT-­‐C	  for	  fluorescent	  imagining.	  	  The	  gain	  and	  exposure	  time	  was	  increased	  or	  decreased	  for	  a	  satisfactory	  image	  of	  
fluorescence.	  	  There	  was	  effort	  to	  keep	  exposure	  time	  small	  so	  the	  fluorescence	  did	  not	  bleach	  out	  due	  to	  prolonged	  light	  exposure.	  	  This	  was	  done	  with	  each	  experimental	  group	  multiple	  times	  for	  best	  image.	  	  All	  imaging	  was	  done	  in	  the	  dark,	  and	  the	  cells	  were	  disposed	  of	  after	  imaging.	  
	  
Flow	  Cytometry	  	   Prep	  	  	  	   	   If	  flow	  cytometry	  was	  employed	  after	  fluorescence	  imaging,	  the	  cells	  were	  taken	  back	  to	  the	  cell	  culture	  hood	  and	  washed	  with	  PBS	  two	  more	  times.	  The	  PBS	  was	  aspirated	  off,	  and	  100ul	  of	  trypsin	  was	  added	  to	  each	  well	  and	  incubated	  at	  37	  degrees	  Celsius	  for	  3	  or	  4	  minutes.	  	  The	  cells	  were	  collected	  off	  of	  the	  well	  bottom	  with	  new	  media	  added	  and	  centrifuged	  for	  5	  minutes	  at	  1500	  rpm.	  	  All	  media	  and	  trypsin	  was	  aspirated	  off	  and	  the	  cells	  were	  resuspended	  in	  200ul	  of	  PBS	  for	  each	  sample	  run.	  	  Depending	  on	  volume	  of	  cells	  collected,	  usually	  3	  samples	  to	  run	  for	  each	  experimental	  group.	  	  During	  the	  time	  of	  cell	  sample	  collection	  the	  flow	  cytometer	  was	  prepared.	  	  First	  it	  was	  turned	  on	  and	  warmed	  up	  for	  about	  fifteen	  minutes.	  	  The	  flow	  startup	  was	  then	  initiated.	  	  Following	  the	  flow	  startup,	  the	  FIT-­‐C	  mode	  was	  calibrated	  using	  appropriate	  calibration	  beads.	  	  Once	  the	  calibration	  test	  was	  complete,	  the	  flow	  cytometer	  was	  ready	  for	  use.	  	   Data	  Collection	  
	   	   The	  negative	  control	  was	  ran	  first,	  to	  fix	  the	  x	  and	  y	  axis	  of	  the	  flow	  cytometer	  plot	  and	  to	  fix	  the	  appropriate	  cell	  population	  region.	  	  Once	  conditions	  were	  set	  satisfactory	  each	  other	  sample	  was	  ran.	  	  Once	  each	  sample	  was	  ran,	  the	  
population	  two	  region	  was	  adjusted	  to	  each	  run,	  which	  separated	  the	  fluorescent	  region	  from	  normal	  non-­‐fluorescent	  region.	  	  Once	  all	  samples	  were	  ran,	  the	  flow	  cytometer	  machine	  was	  shut	  down	  by	  first	  completing	  the	  flow	  shut-­‐down	  process.	  All	  of	  the	  samples	  were	  all	  disposed	  of	  afterward.	  	  
Results	  	  	   Transfection	  without	  chitosan	  is	  pictured	  below	  in	  figures	  six	  and	  seven.	  	  This	  shows	  the	  early	  transfection	  experiments	  using	  50,	  and	  100	  MOI.	  	  The	  transfection	  difference	  from	  50	  to	  100	  MOI	  does	  make	  a	  slight	  difference	  in	  fluorescence	  intensity	  shown	  qualitatively	  in	  figures	  6	  and	  7,	  but	  not	  significant	  difference.	  	  This	  was	  true	  for	  this	  batch	  of	  virus,	  but	  subsequent	  batches	  required	  100	  MOI	  for	  complete	  transfection	  and	  fluorescence	  intensity.	  
	  
Figure	  6.	  3T3	  cells	  transfected	  with	  50	  MOI	  adenovirus	  figureA;	  regular	  light	  image	  of	  
cells	  at	  10x	  magnification,	  B;	  FITC	  image	  of	  A.	  	  Cells	  were	  prepared	  for	  this	  image	  
similar	  to	  flow	  cytometry	  preparation.	  Cells	  were	  not	  adhered	  to	  the	  well,	  they	  were	  on	  
a	  glass	  slide.	  
	  
Figure	  7.	  	  3T3	  cells	  transfected	  with	  100	  MOI	  adenovirus	  figureA;	  regular	  light	  image	  
of	  cells	  at	  10x	  magnification,	  B;	  FITC	  image	  of	  A.	  	  Cells	  were	  prepared	  same	  as	  figure	  6	  
cells.	  	   Shown	  in	  figures	  below	  is	  the	  experiment	  of	  transfection	  with	  chitosan.	  Figure	  8	  is	  the	  positive	  control	  for	  transfection	  at	  100	  MOI,	  and	  figure	  9	  is	  transfection	  with	  chitosan	  of	  0.1%	  and	  0.5%.	  	  
	  
	  Figure	  8.	  Positive	  control	  (100MOI)	  of	  experiment	  with	  transfecting	  with	  chitosan	  and	  
magnification	  10x.	  	  Figure	  A	  is	  3T3	  transfected	  cells,	  B;	  FITC	  image	  showing	  
fluorescence,	  C;	  superimposed	  image	  of	  figures	  A	  and	  B	  
	  
	  
Figure	  9.	  Images	  of	  0.1%	  chitosan	  added	  (A	  and	  B)	  and	  0.5%	  chitosan	  added,	  C	  and	  D.	  	  
Figure	  A	  is	  the	  regular	  exposure	  light	  of	  0.1%	  chitosan	  transfection	  at	  magnification	  
10x,	  B	  is	  the	  FITC	  exposed	  image	  of	  field	  A.	  	  Figure	  C	  is	  the	  regular	  light	  exposed	  field	  of	  
0.5%	  chitosan	  at	  magnification	  20x,	  and	  D	  is	  the	  FITC	  exposed	  field	  of	  C.	  
	  
	   The	  data	  from	  fluorescent	  imaging	  shows	  promise	  of	  chitosan’s	  ability	  of	  antiviral	  with	  adenovirus.	  	  The	  positive	  control	  has	  visible	  fluorescence	  in	  the	  FITC	  
image,	  where	  the	  images	  taken	  with	  chitosan	  added	  appear	  to	  have	  no	  fluorescence	  in	  the	  FITC	  image.	  	  Since	  the	  fluorescent	  intensity	  was	  low	  for	  the	  positive	  control,	  flow	  cytometry	  was	  employed	  for	  standalone	  quantitative	  results.	  	   Figures	  10-­‐14	  are	  the	  flow	  cytometry	  data	  of	  negative	  and	  positive	  control,	  0.1%,	  0.5%,	  and	  1%	  chitosan.	  	  	  	  
	  
Figure	  10.	  Negative	  control	  of	  transfection	  experiment.	  Population	  1	  shows	  most	  
healthy	  cell	  growth,	  with	  no	  population	  in	  P2,	  the	  designated	  fluorescence	  population.	  
	  
Figure	  11.	  	  Positive	  control	  of	  transfection	  experiment.	  	  Significant	  peak	  shift	  to	  
fluorescence	  region	  of	  P2.	  
	  
Figure	  12.	  	  0.1%	  chitosan	  added	  to	  adenovirus.	  	  Shows	  little	  amounts	  of	  fluorescence	  
in	  population	  2.	  
	  
Figure	  13.	  0.5%	  chitosan	  added.	  	  Little	  fluorescence	  in	  population	  2,	  although	  cell	  
status	  is	  not	  similar	  to	  negative	  control,	  or	  0.1%.	  Abnormal	  size.	  
	  
Figure	  14.	  1%	  chitosan	  added.	  	  Increased	  fluorescence	  and	  low	  cell	  condition	  and	  
sample	  size,	  as	  seen	  on	  right	  image.	  
	  
Table	  1.	  









	   Chitosan	  has	  displayed	  antiviral	  promise	  with	  gfp-­‐adenovirus	  on	  NIH-­‐3T3	  cells.	  	  Qualitative	  data	  from	  fluorescence	  microscopy	  displays	  significant	  decrease	  in	  fluorescence	  from	  positive	  control	  to	  when	  the	  chitosan	  is	  added	  simultaneously	  with	  virus	  prior	  to	  incubation.	  	  This	  find	  is	  validated	  with	  flow	  cytometry	  data	  showing	  a	  70%	  difference	  of	  fluorescence	  of	  positive	  control	  to	  added	  chitosan,	  see	  table	  1.	  	   Future	  directions	  will	  need	  to	  include	  replication	  of	  this	  experiment	  with	  flow	  cytometry,	  to	  provide	  more	  validation	  of	  the	  results.	  	  In	  addition,	  factors	  to	  the	  experiment	  can	  be	  altered,	  such	  as	  adding	  the	  chitosan	  after	  viral	  transfection	  to	  observe	  the	  antiviral	  potential	  after	  transfection.	  	  Also,	  adding	  less	  chitosan	  ranging	  from	  0.01%-­‐0.1%	  to	  find	  a	  threshold.	  	   Once	  experiments	  are	  validated	  and	  chitosan	  amount	  is	  clarified	  for	  maximum	  antiviral	  activity,	  this	  study	  can	  be	  moved	  into	  animal	  models	  for	  further	  testing	  in-­‐vivo,	  and	  the	  use	  of	  more	  extreme	  virus	  such	  as	  HIV	  and	  Ebola	  to	  test	  the	  efficiency	  of	  chitosan	  as	  an	  antiviral	  with	  a	  wide	  range	  of	  virus.	  	  From	  this	  study,	  it	  is	  possible	  that	  chitosan	  may	  be	  a	  broad-­‐range	  antiviral	  treatment	  but	  further	  studies	  are	  needed	  to	  validate.	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